These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 32058070)

  • 21. Increase of follicular helper T cells skewed toward a Th1 profile in CVID patients with non-infectious clinical complications.
    Turpin D; Furudoi A; Parrens M; Blanco P; Viallard JF; Duluc D
    Clin Immunol; 2018 Dec; 197():130-138. PubMed ID: 30219667
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vedolizumab Therapy in Refractory Enteropathy Associated With CVID.
    Johnson D; Lee G; Weber F
    ACG Case Rep J; 2022 Jan; 9(1):e00721. PubMed ID: 34977264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Common variable immunodeficiency: association between memory B cells and lung diseases.
    Detková D; de Gracia J; Lopes-da-Silva S; Vendrell M; Alvarez A; Guarner L; Vidaller A; Rodrigo MJ; Caragol I; Espanol T; Hernández M
    Chest; 2007 Jun; 131(6):1883-9. PubMed ID: 17400689
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Common variable immunodeficiency (CVID) presenting with malabsorption due to giardiasis.
    Onbaşi K; Günşar F; Sin AZ; Ardeniz O; Kokuludağ A; Sebik F
    Turk J Gastroenterol; 2005 Jun; 16(2):111-3. PubMed ID: 16252205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eosinophilic Gastroenteritis: Clinical Manifestation, Natural Course, and Evaluation of Treatment with Corticosteroids and Vedolizumab.
    Grandinetti T; Biedermann L; Bussmann C; Straumann A; Hruz P
    Dig Dis Sci; 2019 Aug; 64(8):2231-2241. PubMed ID: 30982212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting Integrin α4β7 in Steroid-Refractory Intestinal Graft-versus-Host Disease.
    Fløisand Y; Lundin KEA; Lazarevic V; Kristiansen JD; Osnes LTN; Tjønnfjord GE; Reims HM; Gedde-Dahl T
    Biol Blood Marrow Transplant; 2017 Jan; 23(1):172-175. PubMed ID: 27777142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-tumour necrosis factor-alpha therapy for severe enteropathy in patients with common variable immunodeficiency (CVID).
    Chua I; Standish R; Lear S; Harbord M; Eren E; Raeiszadeh M; Workman S; Webster D
    Clin Exp Immunol; 2007 Nov; 150(2):306-11. PubMed ID: 17822445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Late-onset combined immune deficiency: a subset of common variable immunodeficiency with severe T cell defect.
    Malphettes M; Gérard L; Carmagnat M; Mouillot G; Vince N; Boutboul D; Bérezné A; Nove-Josserand R; Lemoing V; Tetu L; Viallard JF; Bonnotte B; Pavic M; Haroche J; Larroche C; Brouet JC; Fermand JP; Rabian C; Fieschi C; Oksenhendler E;
    Clin Infect Dis; 2009 Nov; 49(9):1329-38. PubMed ID: 19807277
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patients.
    Van den Berghe N; Verstockt B; Tops S; Ferrante M; Vermeire S; Gils A
    J Gastroenterol Hepatol; 2019 Jul; 34(7):1175-1181. PubMed ID: 30589948
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical picture and treatment of 2212 patients with common variable immunodeficiency.
    Gathmann B; Mahlaoui N; ; Gérard L; Oksenhendler E; Warnatz K; Schulze I; Kindle G; Kuijpers TW; ; van Beem RT; Guzman D; Workman S; Soler-Palacín P; De Gracia J; Witte T; Schmidt RE; Litzman J; Hlavackova E; Thon V; Borte M; Borte S; Kumararatne D; Feighery C; Longhurst H; Helbert M; Szaflarska A; Sediva A; Belohradsky BH; Jones A; Baumann U; Meyts I; Kutukculer N; Wågström P; Galal NM; Roesler J; Farmaki E; Zinovieva N; Ciznar P; Papadopoulou-Alataki E; Bienemann K; Velbri S; Panahloo Z; Grimbacher B;
    J Allergy Clin Immunol; 2014 Jul; 134(1):116-26. PubMed ID: 24582312
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists.
    Feagan BG; Rubin DT; Danese S; Vermeire S; Abhyankar B; Sankoh S; James A; Smyth M
    Clin Gastroenterol Hepatol; 2017 Feb; 15(2):229-239.e5. PubMed ID: 27639327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Altered Microbiota, Impaired Quality of Life, Malabsorption, Infection, and Inflammation in CVID Patients With Diarrhoea.
    van Schewick CM; Nöltner C; Abel S; Burns SO; Workman S; Symes A; Guzman D; Proietti M; Bulashevska A; Moreira F; Soetedjo V; Lowe DM; Grimbacher B
    Front Immunol; 2020; 11():1654. PubMed ID: 32849570
    [No Abstract]   [Full Text] [Related]  

  • 33. Systemic Chemokine Levels with "Gut-Specific" Vedolizumab in Patients with Inflammatory Bowel Disease-A Pilot Study.
    Zwicker S; Lira-Junior R; Höög C; Almer S; Boström EA
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28829369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Cross-Sectional Study of the Prevalence of Gastrointestinal Symptoms and Pathology in Patients With Common Variable Immunodeficiency.
    Jørgensen SF; Reims HM; Frydenlund D; Holm K; Paulsen V; Michelsen AE; Jørgensen KK; Osnes LT; Bratlie J; Eide TJ; Dahl CP; Holter E; Tronstad RR; Hanevik K; Brattbakk HR; Kaveh F; Fiskerstrand T; Kran AB; Ueland T; Karlsen TH; Aukrust P; Lundin KE; Fevang B
    Am J Gastroenterol; 2016 Oct; 111(10):1467-1475. PubMed ID: 27527747
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-α4β7 integrin monoclonal antibody (vedolizumab) for the treatment of steroid-resistant severe intestinal acute graft-versus-host disease.
    Danylesko I; Bukauskas A; Paulson M; Peceliunas V; Gedde-Dahl D Y T; Shimoni A; Shouval R; Griskevicius L; Floisand Y; Nagler A
    Bone Marrow Transplant; 2019 Jul; 54(7):987-993. PubMed ID: 30356163
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
    Ungar B; Kopylov U; Yavzori M; Fudim E; Picard O; Lahat A; Coscas D; Waterman M; Haj-Natour O; Orbach-Zingboim N; Mao R; Chen M; Chowers Y; Eliakim R; Ben-Horin S
    Clin Gastroenterol Hepatol; 2018 May; 16(5):697-705.e7. PubMed ID: 29223444
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease.
    Mahadevan U; Vermeire S; Lasch K; Abhyankar B; Bhayat F; Blake A; Dubinsky M
    Aliment Pharmacol Ther; 2017 Apr; 45(7):941-950. PubMed ID: 28169436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The safety of vedolizumab for the treatment of ulcerative colitis.
    Novak G; Hindryckx P; Khanna R; Jairath V; Feagan BG
    Expert Opin Drug Saf; 2017 Apr; 16(4):501-507. PubMed ID: 28276855
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis.
    Sandborn WJ; Baert F; Danese S; Krznarić Ž; Kobayashi T; Yao X; Chen J; Rosario M; Bhatia S; Kisfalvi K; D'Haens G; Vermeire S
    Gastroenterology; 2020 Feb; 158(3):562-572.e12. PubMed ID: 31470005
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The enteropathy associated with common variable immunodeficiency: the delineated frontiers with celiac disease.
    Malamut G; Verkarre V; Suarez F; Viallard JF; Lascaux AS; Cosnes J; Bouhnik Y; Lambotte O; Béchade D; Ziol M; Lavergne A; Hermine O; Cerf-Bensussan N; Cellier C
    Am J Gastroenterol; 2010 Oct; 105(10):2262-75. PubMed ID: 20551941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.